سعر مولنوبيرافير راميدا 200 مجم 40 كبسولة 2025

Egyptian Molnupiravir-Rameda 200 mg 40 capsules: molnupiravir 200 mg oral capsules, pack of 40, by Rameda (Tenth of Ramadan for Pharmaceutical Industries).

• Treatment of mild to moderate COVID-19 in adults with a positive SARS-CoV-2 test and at least one risk factor for severe illness.Population: Adults with mild to moderate COVID-19 and risk factor(s)MHRA / eMC

• Most common adverse reactions (≥1%): diarrhoea (2%), nausea (1%), dizziness (1%), mostly mild or moderate.International label, same formulation · MHRA / eMC

• Hypersensitivity to molnupiravir or to any of the excipients.International label, same formulation · MHRA / eMC

• Hypersensitivity reactions have been reported; discontinue if clinically significant hypersensitivity occurs. Not a substitute for COVID-19 vaccination.International label, same formulation · MHRA / eMC

• Major drug-metabolising enzymes / transporters (general)Based on limited data and in vitro studies, clinically meaningful interactions with concomitant medicines are considered unlikely; no clinical interaction studies performed.MHRA / eMC

• No human pregnancy data; animal studies showed reproductive toxicity. Not recommended during pregnancy. Women of childbearing potential should use effective contraception during treatment and for 4 days after the last dose.International label, same formulation · MHRA / eMC
• Unknown whether molnupiravir or metabolites are present in human milk. Breast-feeding not recommended during treatment and for 4 days after the last dose.International label, same formulation · MHRA / eMC

• Molnupiravir: Prodrug metabolised to NHC; NHC-TP causes viral error catastrophe in SARS-CoV-2 RNA replication.